Impact of Neuraminidase Mutations Conferring Influenza Resistance to Neuraminidase Inhibitors in the N1 and N2 Genetic Backgrounds

Subtype-specific neuraminidase (NA) mutations conferring resistance to NA inhibitors (NAIs) have been reported during in vitro passages and in clinic. In this study, we evaluated the impact of various NA mutations (E119A/G/V, H274Y, R292K and N294S) on the susceptibility profiles to different NAIs (oseltamivir, zanamivir and peramivir) using recombinant NA proteins of influenza A/WSN/33 (H1N1) and A/Sydney/5/97-like (H3N2) viruses. In the N1 subtype, the E119V mutation conferred cross-resistance to oseltamivir, zanamivir and peramivir [1,727–2,144 and 5,050-fold increase in IC50 values compared with wild-type (WT)] whereas only oseltamivir-resistance (1,028-fold increase in IC50) was conferred by the same mutation in the N2 subtype. The N294S mutation conferred resistance to oseltamivir in both the N1 and N2 subtypes (197- and 1,879-fold increase in IC50 values, respectively) whereas the H274Y mutation conferred resistance to oseltamivir (754-fold increase) and peramivir (260-fold increase) in the N1 subtype only. The virulence of reverse genetics-rescued A/WSN/33 viruses harbouring H274Y and N294S NA mutations was investigated in Balb/c mice. The WT and H274Y recombinants had identical LD50 values (103 PFUs) and generated similar viral lung titres, whereas a higher LD50 (104 PFUs) and a 1-log decrease in viral lung titres were obtained with the N294S mutant. This study shows that some NA mutations at framework residues may confer resistance to one or three NAIs depending on the viral subtype. It suggests that certain drug-resistant NA mutants may still be virulent although additional studies using clinical isolates are needed to confirm our results.

[1]  Y. Guan,et al.  Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia , 2004, Nature.

[2]  R. Webster,et al.  Neuraminidase Inhibitor-Resistant Influenza Viruses May Differ Substantially in Fitness and Transmissibility , 2005, Antimicrobial Agents and Chemotherapy.

[3]  L. Gubareva,et al.  Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. , 2003, The New England journal of medicine.

[4]  F. Hayden,et al.  Evaluation of Neuraminidase Enzyme Assays Using Different Substrates To Measure Susceptibility of Influenza Virus Clinical Isolates to Neuraminidase Inhibitors: Report of the Neuraminidase Inhibitor Susceptibility Network , 2003, Journal of Clinical Microbiology.

[5]  Yoshihiro Kawaoka,et al.  oseltamivir: descriptive study , 2022 .

[6]  N. Roberts,et al.  Treatment of influenza with neuraminidase inhibitors: virological implications. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[7]  R. Webster,et al.  Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en , 1997, Journal of virology.

[8]  F. Hayden,et al.  Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. , 2001, The Journal of infectious diseases.

[9]  Hideo Goto,et al.  Avian flu: Isolation of drug-resistant H5N1 virus , 2005, Nature.

[10]  Guy Boivin,et al.  Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. , 2002, Antiviral research.

[11]  Yi Guan,et al.  Oseltamivir resistance during treatment of influenza A (H5N1) infection. , 2005, The New England journal of medicine.

[12]  V. Stoll,et al.  In Vitro Selection and Characterization of Influenza A (A/N9) Virus Variants Resistant to a Novel Neuraminidase Inhibitor, A-315675 , 2002, Journal of Virology.

[13]  J. McKimm-Breschkin.  Neuraminidase inhibitors for the treatment and prevention of influenza , 2002, Expert opinion on pharmacotherapy.

[14]  A. Monto,et al.  Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. , 2004, The Journal of infectious diseases.

[15]  F. Hayden,et al.  Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. , 2006, The Journal of infectious diseases.

[16]  M. Lawrence,et al.  Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase , 1993, Journal of virology.

[17]  J. Oxford,et al.  The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. , 2002, Antiviral research.

[18]  M. Potier,et al.  Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. , 1979, Analytical biochemistry.

[19]  A. Monto,et al.  Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. , 2002, Antiviral research.

[20]  Larisa V. Gubareva,et al.  Comparison of the Activities of Zanamivir, Oseltamivir, and RWJ-270201 against Clinical Isolates of Influenza Virus and Neuraminidase Inhibitor-Resistant Variants , 2001, Antimicrobial Agents and Chemotherapy.

[21]  P. Ward,et al.  Oral oseltamivir treatment of influenza in children , 2001, The Pediatric infectious disease journal.

[22]  F. Hayden,et al.  Plaque inhibition assay for drug susceptibility testing of influenza viruses , 1980, Antimicrobial Agents and Chemotherapy.

[23]  A. García-Sastre,et al.  Chimeric Influenza A Viruses with a Functional Influenza B Virus Neuraminidase or Hemagglutinin , 2003, Journal of Virology.

[24]  G. Boivin,et al.  A Reverse Genetics Study of Resistance to Neuraminidase Inhibitors in An Influenza A/H1N1 Virus , 2003, Antiviral therapy.

[25]  H. Goto,et al.  Mutations affecting the sensitivity of the influenza virus neuraminidase to 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid. , 1997, Virology.

[26]  G. Boivin,et al.  Characterization of 2 influenza A(H3N2) clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene. , 2002, The Journal of infectious diseases.

[27]  H. Jackson,et al.  Management of Influenza , 2000 .

[28]  R. Sidwell,et al.  Characterization of Human Influenza Virus Variants Selected In Vitro in the Presence of the Neuraminidase Inhibitor GS 4071 , 1998, Antimicrobial Agents and Chemotherapy.

[29]  R. Bethell,et al.  In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir. , 1999, Virology.

[30]  G. Air,et al.  Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. , 1995, Virology.

[31]  R. Webster,et al.  Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en , 1996, Journal of virology.

[32]  K. Bush,et al.  A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding. , 2003, Antiviral research.

[33]  Vasiliy P. Mishin,et al.  Susceptibilities of Antiviral-Resistant Influenza Viruses to Novel Neuraminidase Inhibitors , 2005, Antimicrobial Agents and Chemotherapy.

[34]  P. Colman,et al.  Mutations in a Conserved Residue in the Influenza Virus Neuraminidase Active Site Decreases Sensitivity to Neu5Ac2en-Derived Inhibitors , 1998, Journal of Virology.

[35]  P. Colman,et al.  Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en. , 1995, Virology.

[36]  J. Oxford,et al.  Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. , 2002, Antiviral research.

[37]  D. Mendel,et al.  Mechanism by Which Mutations at His274 Alter Sensitivity of Influenza A Virus N1 Neuraminidase to Oseltamivir Carboxylate and Zanamivir , 2002, Antimicrobial Agents and Chemotherapy.